AGP Executive Report
Last update: 3 hours agoRoyal Health Update: Norway’s Princess Ingrid Alexandra has cut her bachelor’s degree at the University of Sydney short to return home as Crown Princess Mette-Marit’s pulmonary fibrosis worsens, with Crown Prince Haakon also flying back early from Japan to support her. Rare Disease & Access to Care: A Swedish rare-disease report says patients wait an average of 651 days for newly authorised orphan drugs to become available, pointing to slow company follow-through and complex national pricing and approval steps. Cancer Breakthrough (Norway included): A major OPTIMA trial using the Prosigna genomic test (including patients from Norway) suggests many breast cancer patients may safely avoid chemotherapy by better matching treatment to tumor biology. Infectious Disease (Travel Safety): The cruise ship MV Hondius, linked to a hantavirus outbreak, has been cleared after deep cleaning and disinfection in Rotterdam and is set to sail again from Norway’s Arctic route. Health Tech/Policy: Norway’s Prison and Probation Service awarded SuperCom a new electronic monitoring contract, expanding GPS and RF-based offender tracking across the country.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![Swedish rare disease patients endure longer wait for new medicines [Advocacy Lab]](https://www.euractiv.com/content/uploads/sites/2/2026/06/GettyImages-1299083653.jpg)
